

Migraine Prevention Agents - Pennsylvania Prior Authorization Request Form

Please complete this <u>entire</u> form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Member Information				Prescriber Information				
Member Name:			Provider Name:	Provider Name:				
Member ID:			NPI#:	IPI#: Specialty:		<i>t</i> :		
Date Of Birth:			Office Phone:	Office Phone:				
Street Address:			Office Fax:	Office Fax:				
City:	State:	ZIP Code:	Office Street Addre	Office Street Address:				
Phone:	Allergies	:	City:	State: ZIP Code:		ZIP Code:		
Is the requested medication: New or Continuation of Therapy? If continuation, list start date: Is this patient currently hospitalized? Yes No If recently discharged, list discharge date: Is this member pregnant? Yes No If yes, what is this member's due date?								
		Medicat	tion Information					
Medication:					Strength:			
Directions for use:					Quantity:			
Medication Administered	d: ☐ Self-Admini	stered Physic	ian's Office ☐ Other	r:				
		Clinic	al Information					
What is the patient's diagnosis for the medication being requested?								
. ,								
Are there any supporting laboratory or test results related to the patient's diagnosis? (Please specify or provide documentation)								
			n Trials / Contrai					
			uhcprovider.com for a					
What medication(s) does length of trial, and reason				<u>LL</u> medication	n(s)/streng	nths tried, directions,		
What medication(s) does associated contraindication					ALL med	ication(s) with the		
Additional information that may be important for this review								



Migraine Prevention Agents - Pennsylvania Prior Authorization Request Form

Member First	st name: Member Last name: Member Do	DB:						
Clinical and Drug Specific Information								
ALL REQUESTS								
	Does the patient have one of the following diagnoses? (If yes, check which applies)							
□ Yes □ No								
	□ Migraine with or without aura							
□ Yes □ No	Was the diagnosis confirmed according to the current International Headache Society Classification of Headache Disorders?							
	Is the requested medication prescribed by or in consultation with one of the following? (If yes, check which applies)							
□ Yes □ No	□ Neurologist							
	□ Headache specialist who is certified in headache medicine by the United Council for Neurologic							
	Subspecialties (UCNS)							
□ Yes □ No	Does the patient have a contraindication to the prescribed medication?							
□ Yes □ No	Is the patient currently using a migraine prevention agent?							
	If yes to the above question, do any of the following apply? (If yes, check w							
□ Yes □ No	□ Patient will discontinue use of that migraine prevention agent prior to starting	the requested migraine						
□ Not applicable	prevention agent	agents that is supported by						
	□ Patient has a medical reason for concomitant use of both migraine prevention agents that is supported by peer-reviewed literature or national treatment guidelines							
	If the request is for a non-preferred medication, does the patient have a his							
□ Yes □ No	contraindication, or intolerance to the preferred Migraine Prevention Agen	ts approved or medically						
	accepted for the patient's diagnosis or indication? (If yes, complete "Previous Medication Trials/Contraindications" section on first	nage)						
	QULIPTA	Jugo)						
□ Yes □ No								
	If yes to the above question, do any of the following apply? (If yes, check w	which annlies)						
□ Yes □ No								
□ Not applicable	ple ☐ Patient has a medical reason for concomitant use of both gepants that is supp							
	literature or national treatment guidelines							
	EPISODIC CLUSTER HEADACHE							
	Does the patient have a documented history of therapeutic failure, contrain							
□ Yes □ No	at least ONE other preventive medication recommended by current consensus guidelines for episodic cluster headache (such as guidelines from the American Academy of Neurology, American Academy							
l les l'ill	of Family Physicians, American Headache Society)?	ology, American Academy						
	(If yes, complete "Previous Medication Trials/Contraindications" section on first	page)						
	MIGRAINE PREVENTION							
□ Yes □ No	Is there documentation of baseline average number of migraine days and	neadache days per month?						
□ Yes □ No	Has the patient averaged four or more migraine days per month over the p	revious three months?						
	Does the patient have a history of therapeutic failure of at least one prever	ntive medication from any of						
	the following three classes? (If yes, check which applies & complete "Previous Medication Trials/Contraindic	ations" section on first page)						
□ Yes □ No	□ Beta-blockers (e.g., metoprolol, propranolol, timolol)	ations section on mist page)						
	☐ Antidepressants (e.g., amitriptyline, venlafaxine)							
	□ Anticonvulsants (e.g., topiramate, valproic acid, divalproex)							
	Does the patient have a contraindication or intolerance that prohibits a tria	I of at least one						
□ Yes □ No	preventive medication from any of the following three classes?	ations" soction on first nage)						
	(If yes, check which applies & complete "Previous Medication Trials/Contraindic Beta-blockers (e.g., metoprolol, propranolol, timolol)	auons section on ilist page)						
	□ Antidepressants (e.g., amitriptyline, venlafaxine)							
	☐ Anticonvulsants (e.g., topiramate, valproic acid, divalproex)							



Migraine Prevention Agents - Pennsylvania Prior Authorization Request Form

Member First name:		Member Last name:	Member DOB:				
CONTINUATION OF THERAPY - EPISODIC CLUSTER HEADACHE							
□ Yes □ No	Is there documentation of a positive clinical response as evidenced by a reduction in cluster headache frequency from baseline?						
CONTINUATION OF THERAPY - MIGRAINE PREVENTION							
□ Yes □ No	Does the patient have a reduction in the average number of migraine days or headache days per month from baseline?						
□ Yes □ No	Has the patient experienced a decrease in severity or duration of migraines from baseline?						
Provider Si	gnature:		Date:				

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.